Alimentation and Diabetes in Lanzarote - ADILAN: a Pilot Trial

This study has been completed.
Sponsor:
Collaborators:
Cabildo de Lanzarote
Ayuntamiento de Teguise
Ayuntamiento de Arrecife
Information provided by (Responsible Party):
Maelán Fontes-Villalba, Lund University
ClinicalTrials.gov Identifier:
NCT01891955
First received: June 28, 2013
Last updated: March 20, 2014
Last verified: March 2014

June 28, 2013
March 20, 2014
November 2013
February 2014   (final data collection date for primary outcome measure)
  • Fasting fructosamine [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Fasting glucagon [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Fasting HbA1c [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Fasting glucagon [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
Complete list of historical versions of study NCT01891955 on ClinicalTrials.gov Archive Site
  • Area under the curve for glucose (AUC glucose0-120) at the oral glucose tolerance test [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Area under the curve for glucagon (AUC glucagon0-120) at the oral glucose tolerance test [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Fasting plasma glucose [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Total cholesterol [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Low-density lipoprotein (LDL) cholesterol [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • High-density lipoprotein (HDL) cholesterol [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Triglycerides [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Systolic and diastolic blood pressure [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • High-sensitive C-reactive protein [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Waist circumference [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Hip circumference [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Sagittal abdominal diameter [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Tricipital, bicipital, suprailiac and subscapular skinfold thickness [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Satiation measured on a likert scale at food intake during 4 consecutive days [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Quality of life using a validated spanish version of the SF-36 questionnaire [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Change in medication [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Body weight [ Time Frame: To be assessed at baseline and after 4, 10 and 14 weeks ] [ Designated as safety issue: No ]
  • Fasting HbA1c [ Time Frame: Laboratory tests will be performed at baseline and after 4, 10 and 14 weeks ]
  • Area under the curve for glucose (AUC glucose0-120) at the oral glucose tolerance test [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Area under the curve for glucagon (AUC glucagon0-120) at the oral glucose tolerance test [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Fasting plasma glucose [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Total cholesterol [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Low-density lipoprotein (LDL) cholesterol [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • High-density lipoprotein (HDL) cholesterol [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Triglycerides [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Systolic and diastolic blood pressure [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • High-sensitive C-reactive protein [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Laboratory tests will be performed at baseline and after 4, 8 and 12 weeks
  • Waist circumference [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Anthropometric measurements will be performed at baseline and after 4, 8 and 12 weeks
  • Hip circumference [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Anthropometric measurements will be performed at baseline and after 4, 8 and 12 weeks
  • Sagittal abdominal diameter [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Anthropometric measurements will be performed at baseline and after 4, 8 and 12 weeks
  • Tricipital, bicipital, abdominal and subscapular skinfold thickness [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Anthropometric measurements will be performed at baseline and after 4, 8 and 12 weeks
  • Satiation measured on a likert scale at food intake during 4 consecutive days [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    To be assessed at baseline and after 4, 8 and 12 weeks
  • Quality of life using a validated spanish version of the SF-36 questionnaire [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    To be assessed at baseline and after 4, 8 and 12 weeks
  • Change in medication [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    To be assessed at baseline and after 4, 8 and 12 weeks
  • Body weight [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Anthropometric measurements will be performed at baseline and after 4, 8 and 12 weeks
Not Provided
Not Provided
 
Alimentation and Diabetes in Lanzarote - ADILAN: a Pilot Trial
Alimentation and Diabetes in Lanzarote - ADILAN: a Randomized Cross-over Pilot Trial Comparing a Healthy Diet With Grains and Dairy to a Healthy Diet Without Grains and Dairy in Patients With Type 2 Diabetes

The purpose of this study is to compare two healthy diets (according to official Spanish guidelines) that have been shown to be effective in the treatment of type 2 diabetes in order to see if one is better than the other.

Another goal is to test the hypothesis that food choice has metabolic effects that are independent of macro/micronutrient composition, fiber content, glycemic load and weight loss in the treatment of type 2 diabetes.

There is some uncertainty with respect to the optimal dietary treatment of type 2 diabetes. In addition to energy balance, macronutrient composition, dietary fiber and glycemic load, increasing evidence suggests that the direct endocrine effects of food may be important.

In this trial, the intervention is based on two diets. The healthy diet with grains and dairy is based on whole grains, low-fat dairy, fish, shellfish, fruit, vegetables, legumes, eggs, nuts and refined vegetable oils rich in monounsaturated fatty acids (this is called "healthy diet A"). The healthy diet without grains and dairy is based on fish, shellfish, lean meat, fruit, vegetables, root vegetables, eggs and nuts, but excludes grains, legumes, refined vegetable oils, dairy products and salt (this is called "healthy diet B"). Both diets were classified as very healthy using validated nutritional software, and are considered healthy regarding macronutrient composition, fiber, mineral and vitamin intake according to the official Spanish dietary guidelines. The macro and micronutrient ratios, fiber content and glycemic load in healthy diet A and healthy diet B have been set to be equal.

The goal is to include 15 patients (>18 years) with medical diagnosis of type 2 diabetes, with or without medication, and increased waist circumference (≥80 cm for women and ≥94 cm for men), to a cross-over trial during two periods of 4-weeks separated by a 6-week washout period.

Lunch will be served in a hospital kitchen for control of nutrient intake, while the rest of meals will be eaten at home according to specific directions.

The working hypothesis of this study is that food choice has beneficial effects on the control of glucose beyond macro/micronutrient composition, fiber content, glycemic load and weight loss.

This study will provide information on whether food choice and diet quality has greater impact than macro/micronutrient composition, fiber content, glycemic load and weight loss in glucose control in patients with type 2 diabetes, and the need to conduct a long-term trial testing our hypothesis.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 2 Diabetes
  • Behavioral: Healthy diet A
    Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called "healthy diet with grains and dairy"). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.
  • Behavioral: Healthy diet B
    Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called "healthy diet without grains and dairy"). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.
  • Active Comparator: Diet A
    Healthy diet with grains and dairy
    Intervention: Behavioral: Healthy diet A
  • Active Comparator: Diet B
    Healthy diet without grains and dairy
    Intervention: Behavioral: Healthy diet B

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
February 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Medical diagnosis of type 2 diabetes
  • Increased waist circumference (≥80 cm for women and ≥94 cm for men)
  • Unaltered medical diabetes treatment since three months before start of study
  • Stable weight (varied less than 5%) since three months before start of study
  • HbA1c ≥6.0%

Exclusion Criteria:

  • Creatinine >130 μmol/L
  • Change of treatment with betablocker last 3 months
  • Change of treatment with thyroid hormone substitution last 3 months
  • Treatment with anticoagulant medication
  • Oral or injected steroid treatment
  • Elevated liver enzymes (AST, ALT, ALP, GPT > 4 times their respective upper reference value)
  • Physical or psychical illness, or changes in personal circumstances that make it impossible for the patient to continue in the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01891955
MFV-ADI-2013-01
Not Provided
Maelán Fontes-Villalba, Lund University
Lund University
  • Cabildo de Lanzarote
  • Ayuntamiento de Teguise
  • Ayuntamiento de Arrecife
Not Provided
Lund University
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP